TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing expected by the end of the year Tessera to receive $150 ...
Ensoma, an in vivo cellular engineering company with a mission to advance the future of medicine through one-time therapies, today announced that the first patient has been dosed in the company's ...
CRISPR technology, a revolutionary tool in genetic engineering, has empowered Lambert's iGEM team to tackle a significant health issue: Lyme disease, which affects nearly half a million Americans ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback